Free Trial
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Galmed Pharmaceuticals logo
$1.83 -0.50 (-21.46%)
Closing price 04:00 PM Eastern
Extended Trading
$1.90 +0.08 (+4.10%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Key Stats

Today's Range
$1.77
$2.30
50-Day Range
$1.19
$2.33
52-Week Range
$1.15
$23.80
Volume
1.14 million shs
Average Volume
1.35 million shs
Market Capitalization
$3.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Galmed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

GLMD MarketRank™: 

Galmed Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galmed Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galmed Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Galmed Pharmaceuticals has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Galmed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    4.17% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently increased by 36.47%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Galmed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Galmed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.17% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently increased by 36.47%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Galmed Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • MarketBeat Follows

    Only 1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Galmed Pharmaceuticals' insider trading history.
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

GLMD Stock Analysis - Frequently Asked Questions

Galmed Pharmaceuticals' stock was trading at $3.19 at the start of the year. Since then, GLMD shares have decreased by 42.6% and is now trading at $1.83.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings results on Thursday, May, 22nd. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter.

Shares of Galmed Pharmaceuticals reverse split on the morning of Monday, May 15th 2023.The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
5/22/2025
Today
7/18/2025
Next Earnings (Estimated)
8/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLMD
CIK
1595353
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($16.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.52 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-32.21%
Return on Assets
-28.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.02
Quick Ratio
9.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.87 per share
Price / Book
0.19

Miscellaneous

Outstanding Shares
1,650,000
Free Float
1,327,000
Market Cap
$3.02 million
Optionable
Not Optionable
Beta
0.60

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:GLMD) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners